Chagas disease and transfusion medicine: A perspective from non-endemic countries

Blood Transfusion

Volumn 13, Issue 4, 2015, Pages 540-550

  Angheben, Andrea ^a   Boix, Lucia ^b   Buonfrate, Dora ^a   Gobbi, Federico ^a   Bisoffi, Zeno ^a   Pupella, Simonetta ^c   Gandini, Giorgio ^d   Aprili, Giuseppe ^e  

^a Hospital Sacro Cuore   (Italy)

^b HOSPITAL DE TERRASSA   (Spain)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

^e SIMTI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZNIDAZOLE; ITRACONAZOLE; NIFURTIMOX; POSACONAZOLE; ANTITRYPANOSOMAL AGENT; NITROIMIDAZOLE DERIVATIVE;

ASYMPTOMATIC DISEASE; BLOOD BANK; BLOOD DONOR; CANADA; CHAGAS DISEASE; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; EUROPE; FRANCE; HUMAN; ITALY; MIGRATION; NONHUMAN; PATHOGEN REDUCTION SYSTEM; REVIEW; RURAL AREA; SOUTH AMERICA; SOUTH AND CENTRAL AMERICA; SPAIN; TRANSFUSION MEDICINE; TRAVEL; TROPICAL DISEASE; TRYPANOSOMA CRUZI; UNITED KINGDOM; UNITED STATES; ZOONOSIS; ADULT; ADVERSE EFFECTS; BLOOD; BLOOD SAFETY; BLOOD TRANSFUSION; DONOR SELECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNOLOGY; FEMALE; HEALTH; HEALTH SERVICE; ISOLATION AND PURIFICATION; LEGISLATION AND JURISPRUDENCE; MALE; MASS SCREENING; NEWBORN; NORTH AMERICA; PARASITEMIA; PARASITOLOGY; PREGNANCY; PREGNANCY COMPLICATION; STANDARDS; TRANSMISSION;

ADULT; BLOOD DONORS; BLOOD SAFETY; BLOOD TRANSFUSION; CHAGAS DISEASE; DONOR SELECTION; EMIGRATION AND IMMIGRATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPE; FEMALE; GLOBAL HEALTH; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INFANT, NEWBORN; LATIN AMERICA; MALE; MASS SCREENING; NIFURTIMOX; NITROIMIDAZOLES; NORTH AMERICA; PARASITEMIA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TRAVEL; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84949674909     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2015.0040-15     Document Type: Review

References (100)

1. Rassi A J r, Rassi A, Marcondes de Rezende J. American trypanosomiasis (Chagas disease). Infect Dis Clin North Am 2012; 26: 275-91.
2. Hotez PJ, Bottazzi ME, Franco-Paredes C, et al. The neglected tropical diseases of Latin America and the Caribbean: A review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis 2008; 2: e300.
3. Strasen J , Williams T, Ertl G, et al. Epidemiology of Chagas disease in Europe: many calculations, little knowledge. Clin Res Cardiol 2014; 103: 1-10.
4. World Hea lth Organization. Sustaining the drive to overcome the global impact of neglected tropical diseases: second WHO report on neglected diseases. Geneva: WHO Press; 2013.
5. Schmunis GA, Yadon ZE. Chagas disease: A Latin American health problem becoming a world health problem. Acta Trop 2010; 115: 14-21.
6. Hotez PJ, Dumonteil E, Betancourt Cravioto M, et al. An unfolding tragedy of Chagas disease in North America. PLoS Negl Trop Dis 2013; 7: e2300.
7. Guerri-Gu ttenberg RA, Ciannameo A, Di Girolamo C, Milei JJ. [Chagas disease: an emerging public health problem in Italy?]. Le Infezioni in Medicina 2009; 17: 5-13. [In Italian.]
8. Shikanai-Yasuda MA, Carvalho NB. Oral transmission of Chagas disease. Clin Infect Dis 2012; 54: 845-52.
9. Wendel S. Transfusion transmitted Chagas disease: is it really under control? Acta Trop 2010; 115: 28-34.
10. Carlier Y, Sosa-Estani S, Luquetti AO, Buekens P. Congenital Chagas disease: an update. Mem Inst Oswaldo Cruz 2015; 110: 363-8.
11. Chin-Hon g PV, Schwartz BS, Bern C, et al. Screening and treatment of Chagas disease in organ transplant recipients in the United States: recommendations from the Chagas in Transplant Working Group. Am J Transplant 2011; 11: 672-80.
12. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 2001; 1: 92-100.
13. Carod-Ar tal FJ, Gascon J. Chagas disease and stroke. Lancet Neurol 2010; 9: 533-42.
14. Flores M A, Trejos A, Paredes AR, Ramos AY. [Strout's concentration method in the diagnosis of acute Chagas disease]. Boletin Chileno de Parasitologia 1966; 21: 38-9. [In Spanish.]
15. Carlier Y, Torrico F, Sosa-Estani S, et al. Congenital Chagas disease: recommendations for diagnosis, treatment and control of newborns, siblings and pregnant women. PLoS Negl Trop Dis 2011; 5: e1250.
16. Brasil P E, De Castro L, Hasslocher-Moreno AM, et al. ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis. BMC Infect Dis 2010; 10: 337.
17. WHO Expe rt Committee on the Control of Chagas Disease. Control of Chagas disease: second report of the WHO expert committee. Geneva: WHO Press; 2002.
18. World He alth Organization. WHO Consultation on International Biological Reference. Preparations for Chagas Diagnostic Tests. Geneva: WHO Press; 2007.
19. Winkler MA, Brashear RJ, Hall HJ, et al. Detection of antibodies to Trypanosoma cruzi among blood donors in the southwestern and western United States. II. Evaluation of a supplemental enzyme immunoassay and radioimmunoprecipitation assay for confirmation of seroreactivity. Transfusion 1995; 35: 219-25.
20. World He alth Organization. Anti-trypanosoma cruzi assays: operational characteristics. Geneva: WHO Press; 2010.
21. Silveira-Lacerda EP, Silva AG, Junior SF, et al. Chagas' disease: application of TESA-blot in inconclusive sera from a Brazilian blood bank. Vox Sang 2004; 87: 204-7.
22. Marcon G E, Andrade PD, de Albuquerque DM, et al. Use of a nested polymerase chain reaction (N-PCR) to detect Trypanosoma cruzi in blood samples from chronic chagasic patients and patients with doubtful serologies. Diagn Microbiol Infect Dis 2002; 43: 39-43.
23. Picka MC , Meira DA, de Carvalho TB, et al. Definition of a diagnostic routine in individuals with inconclusive serology for Chagas disease. Braz J Infect Dis 2007; 11: 226-33.
24. Umezawa ES, Nascimento MS, Kesper N Jr, et al. Immunoblot assay using excreted-secreted antigens of Trypanosoma cruzi in serodiagnosis of congenital, acute, and chronic Chagas' disease. J Clin Microbiol 1996; 34: 2143-7.
25. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States: A systematic review. JAMA 2007; 298: 2171-81.
26. Viotti R , Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: A nonrandomized trial. Ann Intern Med 2006; 144: 724-34.
27. Perez-Mo lina JA, Perez-Ayala A, Moreno S, et al. Use of benznidazole to treat chronic Chagas' disease: A systematic review with a meta-analysis. J Antimicrob Chemother 2009; 64: 1139-47.
28. Marin-Ne to JA, Rassi A Jr, Avezum A Jr, et al. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz 2009; 104 (Suppl 1): 319-24.
29. Apt W, A rribada A, Zulantay I, et al. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: The regression and prevention of electrocardiographic abnormalities during 9 years of follow-up. Ann Trop Med Parasitol 2003; 97: 23-9.
30. Molina I , Gomez i Prat J, Salvador F, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med 2014; 370: 1899-908.
31. Carriler o B, Murcia L, Martinez-Lage L, Segovia M. Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country. Rev Esp Quimioter 2011; 24: 123-6.
32. Perez-Ay ala A, Perez-Molina JA, Norman F, et al. Chagas disease in Latin American migrants: A Spanish challenge. Clin Microbiol Infect 2011; 17: 1108-13.
33. Keenan M , Chaplin JH. A new era for chagas disease drug discovery? Prog Med Chem 2015; 54: 185-230.
34. Pedreira De Freitas JL, Amato Neto V, Sonntag R, et al. [First tests on the accidental transmission of Chagas disease to man by blood transfusion]. Rev Paul Med 1952; 40: 36-40. [In Portuguese.]
35. Mazza S MA, Benitez C, Janzi EZ. Transmision de "Schizotripanum cruzi" al niño por leche de la madre con enfermedad de Chagas. MEPRA Mision de Estudios de Parasitologia Regional Argentina 1936; 28: 6. [In Spanish.]
36. Wendel S . Transfusion-transmitted Chagas' disease. Curr Opin Hematol 1998; 5: 406-11.
37. Hernandez-Becerril N, Mejia AM, Ballinas-Verdugo MA, et al. Blood transfusion and iatrogenic risks in Mexico City. Anti-Trypanosoma cruzi seroprevalence in 43,048 blood donors, evaluation of parasitemia, and electrocardiogram findings in seropositive. Mem Inst Oswaldo Cruz 2005; 100: 111-6.
38. Castro E . Chagas' disease: lessons from routine donation testing. Transfus Med 2009; 19: 16-23.
39. Schmunis GA, Cruz JR. Safety of the blood supply in Latin America. Clin Microbiol Rev 2005; 18: 12-29.
40. Dias JC, Silveira AC, Schofield CJ. The impact of Chagas disease control in Latin America: A review. Mem Inst Oswaldo Cruz 2002; 97: 603-12.
41. Rolo Med ina J. [Blood Safety in the XXI century. Transfusion transmitted infectious diseases. International and Mexican view]. Gac Med Mex 2014; 150: 78-83. [In Spanish.]
42. Grant IH , Gold JW, Wittner M, et al. Transfusion-associated acute Chagas disease acquired in the United States. Ann Intern Med 1989; 111: 849-51.
43. Cimo PL, Luper WE, Scouros MA. Transfusion-associated Chagas' disease in Texas: report of a case. Texas Med 1993; 89: 48-50.
44. Leiby DA , Lenes BA, Tibbals MA, Tames-Olmedo MT. Prospective evaluation of a patient with Trypanosoma cruzi infection transmitted by transfusion. N Engl J Med 1999; 341: 1237-9.
45. Young C, Losikoff P, Chawla A, et al. Transfusion-acquired Trypanosoma cruzi infection. Transfusion 2007; 47: 540-4.
46. Flores-C havez M, Fernandez B, Puente S, et al. Transfusional Chagas disease: parasitological and serological monitoring of an infected recipient and blood donor. Clin Infect Dis 2008; 46: e44-7.
47. Lane DJ, Ward B, Ndao M, et al. Investigation of the second case of transfusion transmitted Chagas disease in Canada. Presented at: 42nd Annual Meeting of the American Society of Hematology, San Francisco, California; 2000.
48. Abalo M, Areal C, Castrillo A, et al. Tracing of one year of Chagas screening at the Centro de Transfusion de Galicia (C.T.G.) concerning a positive blood donor [abstract]. Vox Sang 2007; 93 (Suppl 1): 140.
49. Benjamin RJ, Stramer SL, Leiby DA, et al. Trypanosoma cruzi infection in North America and Spain: evidence in support of transfusion transmission. Transfusion 2012; 52: 1913-21.
50. Schmunis GA. Epidemiology of Chagas disease in nonendemic countries: The role of international migration. Mem Inst Oswaldo Cruz 2007; 102 (Suppl 1): 75-85.
51. Guerri-G uttenberg RA, Grana DR, Ambrosio G, Milei J. Chagas cardiomyopathy: Europe is not spared! Eur Heart J 2008; 29: 2587-91.
52. Jackson Y, Getaz L, Wolff H, et al. Prevalence, clinical staging and risk for blood-borne transmission of Chagas disease among Latin American migrants in Geneva, Switzerland. PLoS Negl Trop Dis 2010; 4: e592.
53. Schmunis GA. Trypanosoma cruzi, the etiologic agent of Chagas' disease: status in the blood supply in endemic and nonendemic countries. Transfusion 1991; 31: 547-57.
54. Nickerso n P, Orr P, Schroeder ML, et al. Transfusionassociated Trypanosoma cruzi infection in a non-endemic area. Ann Intern Med 1989; 111: 851-3.
55. Fores R, Sanjuan I, Portero F, et al. Chagas disease in a recipient of cord blood transplantation. Bone Marrow Transplant 2007; 39: 127-8.
56. Wendel S , Gonzaga AL. Chagas' disease and blood transfusion: A New World problem? Vox Sang 1993; 64: 1-12.
57. Wendel S . Chagas disease: an old entity in new places. Int J Artif Organs 1993; 16: 117-9.
58. Cerisola JA, Rabinovich A, Alvarez M, et al. [Chagas' disease and blood transfusion]. Bol Oficina Sanit Panam 1972; 73: 203-21. [In Spanish.]
59. Kessler DA, Shi PA, Avecilla ST, Shaz BH. Results of lookback for Chagas disease since the inception of donor screening at New York Blood Center. Transfusion 2013; 53: 1083-7.
60. Otani MM , Vinelli E, Kirchhoff LV, et al. WHO comparative evaluation of serologic assays for Chagas disease. Transfusion 2009; 49: 1076-82.
61. Flores-C havez M, Cruz I, Rodriguez M, et al. [Comparison of conventional and non-conventional serological tests for the diagnosis of imported Chagas disease in Spain]. Enferm Infecc Microbiol Clin 2010; 28: 284-93. [In Spanish]
62. World He alth Organization. WHO Consultation on International Biological Reference Preparations for Chagas Diagnostic Tests. Geneva, 2-3 July 2007. Available at: http://www.who.int/bloodproducts/ref-materials/WHO-Report-1st-Chagas-BRP-consultation-7-2007-final.pdf. Accessed on 14/02/2015.
63. Basile L , Jansa JM, Carlier Y, et al. Chagas disease in European countries: The challenge of a surveillance system. Euro Surveill 2011; 16: pii: 19968.
64. Cantey P T, Stramer SL, Townsend RL, et al. The United States Trypanosoma cruzi Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion 2012; 52: 1922-30.
65. Zaniello BA, Kessler DA, Vine KM, et al. Seroprevalence of Chagas infection in the donor population. PLoS Negl Trop Dis 2012; 6: e1771.
66. Appleman MD, Shulman IA, Saxena S, Kirchhoff LV. Use of a questionnaire to identify potential blood donors at risk for infection with Trypanosoma cruzi. Transfusion 1993; 33: 61-4.
67. Garraud O, Andreu G, Elghouzzi MH, et al. Measures to prevent transfusion-associated protozoal infections in nonendemic countries. Travel Med Infect Dis 2007; 5: 110-2.
68. O'Brien SF, Chiavetta JA, Fan W, et al. Assessment of a travel question to identify donors with risk of Trypanosoma cruzi: operational validity and field testing. Transfusion 2008; 48: 755-61.
69. Assal A, Corbi C. [Chagas disease and blood transfusion: an emerging issue in non-endemic countries]. Transfus Clin Biol 2011; 18: 286-91. [In French.]
70. Agapova M, Busch MP, Custer B. Cost-effectiveness of screening the US blood supply for Trypanosoma cruzi. Transfusion 2010; 50: 2220-32.
71. Moraes-S ouza H, Bordin JO, Bardossy L, et al. Prevention of transfusion-associated Chagas' disease: efficacy of white cell-reduction filters in removing Trypanosoma cruzi from infected blood. Transfusion 1995; 35: 723-6.
72. Girones N, Bueno JL, Carrion J, et al. The efficacy of photochemical treatment with methylene blue and light for the reduction of Trypanosoma cruzi in infected plasma. Vox Sang 2006; 91: 285-91.
73. Ramirez LE, Lages-Silva E, Pianetti GM, et al. Prevention of transfusion-associated Chagas' disease by sterilization of Trypanosoma cruzi-infected blood with gentian violet, ascorbic acid, and light. Transfusion 1995; 35: 226-30.
74. Docampo R, Moreno SN, Cruz FS. Enhancement of the cytotoxicity of crystal violet against Trypanosoma cruzi in the blood by ascorbate. Mol Biochem Parasitol 1988; 27: 241-7.
75. Castro E . Photochemical treatment with methylene blue and light as well as freezing of plasma avoids Trypanosoma cruzi transmission by transfusion. Transfusion 2005; 44: SP241.
76. Castro E , Girones N, Bueno JL, et al. The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy-coat platelets. Transfusion 2007; 47: 434-41.
77. Van Voor his WC, Barrett LK, Eastman RT, et al. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 2003; 47: 475-9.
78. Singh Y, Sawyer LS, Pinkoski LS, et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006; 46: 1168-77.
79. Corash L . Inactivation of infectious pathogens in labile blood components: meeting the challenge. Transfus Clin Biol 2001; 8: 138-45.
80. Fast LD, Nevola M, Tavares J, et al. Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graftversus-host disease? Transfusion 2013; 53: 373-81.
81. Tonnetti L, Thorp AM, Reddy HL, et al. Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood. Transfusion 2012; 52: 409-16.
82. Cardo LJ , Salata J, Mendez J, et al. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 2007; 37: 131-7.
83. Wagner S J, Skripchenko A, Salata J, Cardo LJ. Photoinactivation of Trypanosoma cruzi in red cell suspensions with thiopyrylium. Transfus Apher Sci 2007; 37: 23-5.
84. Da Silva CF, Junqueira A, Lima MM, et al. In vitro trypanocidal activity of DB745B and other novel arylimidamides against Trypanosoma cruzi. J Antimicrob Chemother 2011; 66: 1295-7.
85. Moraes-S ouza H, Pianetti GM, Barretto OC, et al. Aminoquinolone WR6026 as a feasible substitute for gentian violet in Chagas' disease prophylaxis in preserved blood for transfusional purposes. Rev Soc Bras Med Trop 2002; 35: 563-9.
86. Bern C, Montgomery SP, Katz L, et al. Chagas disease and the US blood supply. Curr Opin Infect Dis 2008; 21: 476-82.
87. Stramer SL, Foster GA, Krysztof DE, et al. Poster session 1: Apheresis, U.S. blood donor screening for Typanosoma cruzi: clinical studies and first year experience. Vox Sang 2008; 95: 74-326.
88. Stramer S L FG, Townsend R, Krysztof D, et al. Special Issue: Abstract Presentations from the AABB Annual Meeting and TXPO (Reissued December 2008), Trypanosoma cruzi antibody screening in US blood donors: one year experience at the American Red Cross. Abstract P5-020A. Transfusion 2008; 48: 1A-241A.
89. Stramer S L, Townsend RL, Custer B, et al. No evidence of Trypanosoma cruzi incidence in US blood donors: A 4-year study. Abstract P1-020A. Transfusion 2011; 51: 1A-236A.
90. O'Brien S F, Scalia V, Goldman M, et al. Selective testing for Trypanosoma cruzi: The first year after implementation at Canadian Blood Services. Transfusion 2013; 53: 1706-13.
91. O'Brien S F, Scalia V, Goldman M, et al. Evaluation of selective screening of donors for antibody to Trypanosoma cruzi: seroprevalence of donors who answer "no" to risk questions. Transfusion 2014; 54: 863-9.
92. Grupo de Trabajo Donación de Sangre e Inmigración MdSyPS. Enfermedad de Chagas y Donacion de Sangre; 2009. Available at: http://www.msssi.gob.es/profesionales/ saludPublica/medicinaTransfusional/publicaciones/docs/ informeChagasJulio09.pdf. Accesses on 14/02/2015.
93. Piron M, Verges M, Munoz J, et al. Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion 2008; 48: 1862-8.
94. Angheben A, Anselmi M, Gobbi F, et al. Chagas disease in Italy: breaking an epidemiological silence. Euro Surveill 2011; 16: pii=19969.
95. Gabrielli S, Girelli G, Vaia F, et al. Surveillance of Chagas disease among at-risk blood donors in Italy: preliminary results from Umberto I Polyclinic in Rome. Blood Transfus 2013; 11: 558-62.
96. Kitchen A D, Hewitt PE, Chiodini PL. The early implementation of Trypanosoma cruzi antibody screening of donors and donations within England: preempting a problem. Transfusion 2012; 52: 1931-9.
97. Requena-M endez A, Albajar-Vinas P, Angheben A, et al. Health policies to control Chagas disease transmission in European countries. PLoS Negl Trop Dis 2014; 8: e3245.
98. Pacific W HO-ROftW. Meeting Report: Informal consultation on Chagas disease in the Western Pacific; 2011. Available at: http://www.wpro.who.int/mvp/documents/Chagas-Meeting-Report.pdf. Accesses on 14/02/2015.
99. Farrugia A. The mantra of blood safety: time for a new tune? Vox Sang 2004; 86: 1-7.
100. Castro E , Gonzalez LM, Rubio JM, et al. The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets. Transfusion 2014; 54: 2207-16.